Survodutide's cardiovascular outcomes trial reaches primary completion

A cardiovascular outcomes trial for survodutide, an investigational weight-management drug also known by its research code BI 456906, has reached primary completion. The trial, called SYNCHRONIZE-CVOT and registered on ClinicalTrials.gov as NCT06077864, enrolled 5,531 people with overweight or obesity to test whether the drug is safe for the heart ^[1]. This makes it the first of the current group of pipeline obesity-drug outcomes trials to finish its main measurement period ^[1].

As of September 14, 2026, the trial's results had not been published ^[1]. Primary completion means the study has finished collecting the data needed to answer its main safety question, but it does not mean the findings have been released or reviewed ^[1]. The ClinicalTrials.gov record for the study describes it as a test of survodutide's cardiovascular safety in people with overweight or obesity, but detailed outcome data, including any breakdown of heart attacks, strokes, or deaths in the drug group versus a comparison group, are not yet available in the public record ^[1].

Survodutide is not an approved medicine in the United States. It is not the same as semaglutide (sold as Ozempic, Wegovy, and Rybelsus) or tirzepatide (sold as Mounjaro and Zepbound), and it is not orforglipron (Foundayo). It remains an experimental compound being studied by its developer through registered clinical trials like this one ^[1].

Cardiovascular outcomes trials, often called CVOTs, are large studies required for many new metabolic drugs. They are designed to rule out unacceptable heart risk and, in some cases, to show a heart benefit. Because SYNCHRONIZE-CVOT is the first such trial in this newer wave of obesity-drug studies to reach this stage, its eventual results will be an early signal for how regulators and doctors think about the whole category of drugs still in the pipeline ^[1].

Why it matters for patients

For people currently using approved GLP-1 medicines like semaglutide or tirzepatide, this specific trial does not change anything about those drugs. It is testing a different, unapproved compound, survodutide, in a study that has not yet reported results ^[1].

For people who are curious about future obesity treatments, reaching primary completion is a checkpoint, not a finish line. The data still need to be analyzed, and the sponsor will decide when and how to release findings. Until results are published, there is no way to know from this record whether survodutide showed a neutral, positive, or negative effect on heart-related events compared with the group it was measured against ^[1].

This trial is also being watched as an early test case. Because it is the first cardiovascular outcomes trial in this new group of obesity drugs to complete its main phase, how its results eventually turn out, and how quickly they are released, may shape expectations for other drugs still being tested for heart safety ^[1].

What happens next

As of September 14, 2026, survodutide's cardiovascular outcomes results had not yet been made public ^[1]. The trial record does not specify an exact date for when full results will be published. Patients and clinicians will need to watch for a formal results announcement, either through an update to the ClinicalTrials.gov record, a scientific conference presentation, or a peer-reviewed publication, before any conclusions can be drawn about the drug's cardiovascular safety profile ^[1].